home / stock / capr / capr news

CAPR News and Press, Capricor Therapeutics Inc. From 07/17/19

Stock Information
Company Name: Capricor Therapeutics Inc.
Stock Symbol: CAPR
Market: NASDAQ
Website: capricor.com
Menu
CAPR CAPR Quote CAPR Short CAPR News CAPR Articles CAPR Message Board
Get CAPR Alerts

News, Short Squeeze, Breakout and More Instantly...
CAPR - Capricor Therapeutics and Parents Project Muscular Dystrophy to Host Webinar to Discuss Interim Analysis of the HOPE-2 Clinical Trial to Treat Patients with Duchenne Muscular Dystrophy

-- Conference Call Today at 1 PM ET/10 AM PT --                                                    LOS ANGELES, July 17, 2019 (GLOBE NEWSWIRE) -- Capricor ...
CAPR - DPZ, ARW among premarket losers

Turquoise Hill Resources TRQ  -31%  after Rio Tinto's Mongolia project expected to be delayed. More news on: China Lending Corporation, Adamis Pharmaceuticals Corporation, Workhorse Group Inc., Stocks on the move, Read more ...

CAPR - CAPR Stock Jumps to New 2019 Highs on Positive CAP-1002 Outcomes

CAPR stock is moving up big as Capricor Therapeutics Inc (NASDAQ:CAPR) announces positive data in a rare disease indication. Big News for Capricor California-based Capricor Therapeutics has been one of the biggest gainers today after the company released positive results from the trial ...

CAPR - CIR, CPE and GLPG among midday movers

Gainers:  Capricor Therapeutics (NASDAQ: CAPR ) +148% . Carolina Trust BancShares (NASDAQ: CART ) +30% . SSLJ.com Limited (YGTY) +29% . Chicken Soup for the Soul Entertainment (NASDAQ: CSSE ) +22% . AVROBIO (NASDAQ: AVRO ) +22% . Mereo BioPharma Group (NASDAQ: MREO ) +21% . Amer...
CAPR - UEC, ADXS among premarket gainers

Capricor Therapeutics (NASDAQ: CAPR ) +95%  on positive CAP-1002 data . More news on: Capricor Therapeutics, Inc., Galapagos NV, Neon Therapeutics, Inc., Stocks on the move, Read more ...

CAPR - Capricor up 45% premarket on positive CAP-1002 data

Thinly traded nano cap Capricor Therapeutics (NASDAQ: CAPR ) is up  45%  premarket on modest volume in response to its announcement of positive six-month data from its Phase 2 clinical trial, HOPE-2 , evaluating lead candidate CAP-1002 in steroid-treated boys and young men with ...

CAPR - Capricor Therapeutics Announces Positive Results from its Interim Analysis in the HOPE-2 Trial to Treat Patients with Duchenne Muscular Dystrophy

--Interim Analysis Showed Statistically Significant Improvements in the Performance of the Upper Limb, Grip Strength and Inspiratory Flow Reserve in the Randomized Double-Blind Placebo Controlled Study -- --Company to Hold Conference Call Today at 5:00 AM PT / 8:00 AM ET--   &#x...
CAPR - Capricor Therapeutics, Inc. (CAPR) CEO Linda Marbán on Q1 2019 Results - Earnings Call Transcript

Capricor Therapeutics, Inc. (CAPR) Q1 2019 Earnings Conference Call May 13, 2019, 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marbán - President and CEO Conference Call Participants Joe Pantginis - H.C. Wainwright Jason McCarthy - Maxim Group Presentati...

CAPR - Data readout from mid-stage study of Capricor's CAP-1002 expected next quarter; shares up 5% after hours

Capricor Therapeutics (NASDAQ: CAPR ) Q1 highlights : More news on: Capricor Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...

CAPR - Capricor Therapeutics beats by $0.03, misses on revenue

Capricor Therapeutics (NASDAQ: CAPR ): Q1 GAAP EPS of -$0.08 beats by $0.03 . More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...

Previous 10 Next 10